BNT162b2
Tozinameran is an RNA vaccine composed of nucleoside-modified mRNA encoding a mutated form of the spike protein of SARS-CoV-2. The vaccination requires two doses given three weeks apart. Pfizer has advanced purchase agreements of about USD 3 billion for providing a licensed vaccine in the United States, European Union, United Kingdom, Japan, Canada, and Peru.